Do you think that, IF, the SOC arm is not surviving incredibly longer than other previous studies, the trial did not halt for efficacy at the 2IA due to some abnormality in enrollment, dropouts, or some other effect the trial halt would have caused? ONTY
I agree. Something is incredibly off from some of the data enrollment curve theories posted on VIC and SA. It would really be odd if the SOC is just miraculously living much longer than many studies are currently showing.
IMO, the trial halt did something to affect things - I personally dont buy the SOC arm is living 36+ months theory
